{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T14:28:55Z","timestamp":1785680935204,"version":"3.56.0"},"reference-count":53,"publisher":"Impact Journals, LLC","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,7,20]]},"DOI":"10.18632\/oncotarget.4015","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T06:29:45Z","timestamp":1442298585000},"page":"18224-18237","source":"Crossref","is-referenced-by-count":81,"title":["Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity"],"prefix":"10.18632","volume":"6","author":[{"given":"Inga","family":"Gr\u00fcnewald","sequence":"first","affiliation":[{"name":"Institute of Pathology, University Hospital of Cologne, Cologne, Germany"},{"name":"Department of Pathology, University Hospital of Muenster, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Vollbrecht","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine","family":"Meinrath","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz F.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas C.","family":"Heukamp","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Drebber","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Beutner","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Bernd","family":"H\u00fcttenbrink","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wardelmann","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Muenster, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital of Cologne, Cologne, Germany"},{"name":"Department of Pathology, University Hospital of Muenster, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital of Cologne, Cologne, Germany"},{"name":"Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarete","family":"Odenthal","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital of Cologne, Cologne, Germany"},{"name":"Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Stenner","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne, Cologne, Germany"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Muenster, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,5,25]]},"reference":[{"key":"1","first-page":"209","volume-title":"Tumours of the Salivary Glands. World Health Organization Classification of Tumours. Pathology and Genetics. Head and Neck Tumours","author":"Sidransky","year":"2005"},{"key":"2","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2005.05.3025","article-title":"Systemic therapy in the palliative management of advanced salivary gland cancers","volume":"24","author":"Licitra","year":"2006","journal-title":"J. Clin. Oncol"},{"key":"3","article-title":"Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers","author":"Andersson","year":"2014","journal-title":"Oral Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1158\/1078-0432.CCR-10-2571","article-title":"New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer","volume":"17","author":"Pao","year":"2011","journal-title":"Clin Cancer Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Garrido","year":"2012","journal-title":"Lancet Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CCC.2011.n.009","article-title":"Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis","volume":"10","author":"Salpeter","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/13543780902806400","article-title":"Treatment of gastrointestinal stromal tumours: imatinib, sunitinib \u2014 and then?","volume":"18","author":"Ahlman","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"8","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ejca.2011.06.052","article-title":"New drugs in melanoma: it's a whole new world","volume":"47","author":"Robert","year":"2011","journal-title":"Eur J Cancer"},{"key":"9","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Bowcock","year":"2010","journal-title":"Science"},{"key":"10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1586\/erm.11.18","article-title":"Next-generation sequencing applied to molecular diagnostics","volume":"11","author":"Reis-Filho","year":"2011","journal-title":"Expert Rev Mol Diagn"},{"key":"11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm.2166","article-title":"Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma","volume":"16","author":"Chen","year":"2010","journal-title":"Nat. Med"},{"key":"12","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1007\/s12105-013-0462-z","article-title":"Fusion oncogenes in salivary gland tumors: molecular and clinical consequences","volume":"7","author":"Stenman","year":"2013","journal-title":"Head. Neck. Pathol"},{"key":"13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ng.2643","article-title":"The mutational landscape of adenoid cystic carcinoma","volume":"45","author":"Huberman","year":"2013","journal-title":"Nat. Genet"},{"key":"14","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1172\/JCI67201","article-title":"Whole exome sequencing of adenoid cystic carcinoma","volume":"123","author":"Hardy","year":"2013","journal-title":"J. Clin. Invest"},{"key":"15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12967-014-0299-6","article-title":"High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma","volume":"12","author":"Ahn","year":"2014","journal-title":"J. Transl. Med"},{"key":"16","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1093\/annonc\/mdt338","article-title":"Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours","volume":"24","author":"Badoual","year":"2013","journal-title":"Ann. Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/modpathol.2012.55","article-title":"Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions","volume":"25","author":"West","year":"2012","journal-title":"Mod. Pathol"},{"key":"18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/modpathol.2009.142","article-title":"High prevalence of PIK3CA\/AKT pathway mutations in papillary neoplasms of the breast","volume":"23","author":"Corless","year":"2010","journal-title":"Mod. Pathol"},{"key":"19","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/bcr3113","article-title":"PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR, and ERBB2-based subgroups","volume":"14","author":"Bieche","year":"2012","journal-title":"Breast Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"e65479","DOI":"10.1371\/journal.pone.0065479","article-title":"PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival","volume":"8","author":"Williamson","year":"2013","journal-title":"PLoS One"},{"key":"21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Macconaill","year":"2013","journal-title":"Nat. Genet"},{"key":"22","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Lawrence","year":"2012","journal-title":"Cell"},{"key":"23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11060-009-9967-4","article-title":"Different molecular patterns in glioblastoma multiforme subtypes upon recurrence","volume":"96","author":"Schackert","year":"2010","journal-title":"J. Neurooncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1349-7006.1999.tb00838.x","article-title":"Rare-type mutations of MMAC1 tumor suppressor gene in human glioma cell lines and their tumors of origin","volume":"90","author":"Kumanishi","year":"1999","journal-title":"Jpn. J. Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10006-012-0350-9","article-title":"Salivary gland carcinomas","volume":"16","author":"Reichert","year":"2012","journal-title":"Oral Maxillofac. Surg"},{"key":"26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","article-title":"Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy","volume":"49","author":"Wang","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol"},{"key":"27","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Mattos","year":"2012","journal-title":"Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Au","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"29","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"Varmus","year":"2005","journal-title":"PLoS Med"},{"key":"30","doi-asserted-by":"crossref","first-page":"e81628","DOI":"10.1371\/journal.pone.0081628","article-title":"Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine","volume":"8","author":"Shi","year":"2013","journal-title":"PLoS One"},{"key":"31","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.oraloncology.2009.01.013","article-title":"KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas","volume":"45","author":"Kosmehl","year":"2009","journal-title":"Oral Oncol"},{"key":"32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12105-013-0506-4","article-title":"HRAS mutations in epithelial-myoepithelial carcinoma","volume":"8","author":"Seethala","year":"2014","journal-title":"Head. Neck. Pathol"},{"key":"33","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/PAS.0b013e3182880d5a","article-title":"PIK3CA mutations and PTEN loss in salivary duct carcinomas","volume":"37","author":"Chiosea","year":"2013","journal-title":"The American journal of surgical pathology"},{"key":"34","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1078-0432.CCR-12-1842","article-title":"Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment","volume":"19","author":"Flaherty","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1200\/JCO.2011.36.2095","article-title":"Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J. Clin. Oncol"},{"key":"36","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1158\/0008-5472.CAN-07-5659","article-title":"PIK3CA mutation\/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab","volume":"68","author":"Mariadason","year":"2008","journal-title":"Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/0008-5472.CAN-08-2466","article-title":"PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies","volume":"69","author":"Bardelli","year":"2009","journal-title":"Cancer Res"},{"key":"38","first-page":"108ra114","article-title":"Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma","volume":"3","author":"Lemmon","year":"2011","journal-title":"Sci. Transl. Med"},{"key":"39","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Wolf","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"40","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1074\/jbc.M705774200","article-title":"c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations","volume":"283","author":"Kim","year":"2008","journal-title":"J. Biol. Chem"},{"key":"41","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Santoro","year":"2004","journal-title":"Oncogene"},{"key":"42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/his.12050","article-title":"Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations","volume":"62","author":"Vukovic","year":"2013","journal-title":"Histopathology"},{"key":"43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2005.06.125","article-title":"Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study","volume":"23","author":"Siu","year":"2005","journal-title":"J. Clin. Oncol"},{"key":"44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/excr.2000.5140","article-title":"TGFbeta signaling and cancer","volume":"264","author":"Hata","year":"2001","journal-title":"Exp. Cell Res"},{"key":"45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/annonc\/10.suppl_4.S56","article-title":"DPC4\/SMAD4 gene alterations in human cancer, and their functional implications","volume":"10","author":"Schutte","year":"1999","journal-title":"Ann. Oncol"},{"key":"46","first-page":"13","article-title":"Alteration of SMAD4 does not participate in tumorigenesis of adenoid cystic carcinoma of the salivary gland","volume":"2","author":"Yokoyama","year":"2009","journal-title":"Mol. Med. Rep"},{"key":"47","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/modpathol.2012.102","article-title":"Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer","volume":"25","author":"Engel-Riedel","year":"2012","journal-title":"Mod. Pathol"},{"key":"48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00019606-200606000-00004","article-title":"Pitfalls in the detection of t(11,22) translocation by fluorescence in situ hybridization and RT-PCR: a single-blinded study","volume":"15","author":"Buettner","year":"2006","journal-title":"Diagn. Mol. Pathol"},{"key":"49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12105-013-0493-5","article-title":"An immunohistochemical panel for reliable differentiation of salivary duct carcinoma and mucoepidermoid carcinoma","volume":"8","author":"McHugh","year":"2014","journal-title":"Head. Neck. Pathol"},{"key":"50","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.9050","article-title":"Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis","volume":"93","author":"Ichien","year":"2001","journal-title":"Cancer"},{"key":"51","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Dahmen","year":"2012","journal-title":"Nat. Genet"},{"key":"52","article-title":"Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients","author":"Nogova","year":"2015","journal-title":"J.Thorac.Oncol"},{"key":"53","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1093\/nar\/gkr407","article-title":"Predicting the functional impact of protein mutations: application to cancer genomics","volume":"39","author":"Sander","year":"2011","journal-title":"Nucleic Acids Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T12:28:01Z","timestamp":1589372881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,25]]},"references-count":53,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2015,7,20]]}},"alternative-id":["4015","26053092"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.4015","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,25]]}}}